Pharmacogenomics and nanotechnology toward advancing personalized medicine

NanoScience and Technology

Volumn 61, Issue , 2012, Pages 115-134

  Vizirianakis, Ioannis S ^a   Amanatiadou, Elsa P ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867008950     PISSN: 14344904     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-24181-9_7     Document Type: Article

References (85)

1. I.S. Vizirianakis, Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping. Clin. Pharmacokinet. 46, 807-824 (2007)
2. G.S. Ginsburg, H.F. Willard, Genomic and personalized medicine: foundations and applications. Transl. Res. 154, 277-287 (2009)
3. M. Pirmohamed, B.K. Park, Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22, 298-305 (2001)
4. I.S. Vizirianakis, Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality? Pharmacogenomics 6, 701-711 (2005)
5. K. Braeckmans, S.C. De Smedt, M. Leblans, R. Pauwels, J. Demeester, Encoding microcarriers: present and future technologies. Nat. Rev. Drug Discov. 1, 447-456 (2002)
6. I.S. Vizirianakis, Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug delivery outcomes. Nanomedicine 7, 11-17 (2011)
7. A.D. Roses, Pharmacogenetics and the practice of medicine. Nature 405, 857-865 (2000)
8. R. Weinshilboum, Inheritance and drug response. N. Engl. J. Med. 348, 529-537 (2003)
9. W.E. Evans, H.L. McLeod. Pharmacogenomics, drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003)
10. I.S. Vizirianakis, Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice. Curr. Drug Deliv. 1, 73-80 (2004)
11. I.S. Vizirianakis, From defining bioinformatics and pharmacogenomics to developing information-based medicine and pharmacotyping in healthcare, in Handbook of Pharmaceutical Biotechnology, ed. by S.C. Gad (Wiley, New York, 2007), pp. 201-228
12. P. Debbage, Targeted drugs and nanomedicine: present and future. Curr. Pharm. Des. 5, 153-172 (2009)
13. C. Huttenhower, O. Hofmann, A quick guide to large-scale genomic data mining. PLoS Comput Biol. 6, e1000779 (2010)
14. I.S. Vizirianakis, Chatzopoulou M., I.D. Bonovolias, I. Nicolaou, V.J. Demopoulos, A.S. Tsiftsoglou, Toward the development of innovative bi-functional agents to induce differentiation and promote apoptosis in leukemia: clinical candidates and perspectives. J. Med. Chem. 53, 6779-6810 (2010)
15. K. Ahn, J. Luo, A. Berg, D. Keefe, R. Wu, Functional mapping of drug response with pharmacodynamic-pharmacokinetic principles. Trends Pharmacol. Sci. 31, 306-311 (2010)
16. T. Lammers, F. Kiessling, W.E. Hennink, G. Storm, Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol. Pharm. 7, 1899-1912 (2010)
17. D.B. Goldstein, S.K. Tate, S.M. Sisodiya, Pharmacogenetics goes genomic. Nat. Rev. Genet. 4, 937-947 (2003)
18. A. Loktionov, Common gene polymorphisms, cancer progression and prognosis. Cancer Lett. 208, 1-33 (2004)
19. J.L. Anderson, J.F. Carlquist, B.D. Horne, J.B. Muhlestein, Cardiovascular pharmacogenomics: current status, future prospects. J. Cardiovasc. Pharmacol. Ther. 8, 71-83 (2003)
20. R. Cacabelos, The application of functional genomics to Alzheimer's disease. Pharmacogenomics 4, 597-621 (2004)
21. C.M. Ulrich, K. Robien, H.L. Mcleod, Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat. Rev. Cancer. 3, 912-920 (2003)
22. I. Sayers, I.P. Hall, Pharmacogenetic approaches in the treatment of asthma. Curr. Allergy Asthma Rep. 5, 101-108 (2005)
23. G. Müller, Personalized prognosis and diagnosis of type 2 diabetes: vision or fiction? Pharmacology 85, 168-187 (2010)
24. J.M. Rusnak, R.M. Kisabeth, D.P. Herbert, D.M. McNeil, Pharmacogenomics: a clinician's primer on emerging technologies for improved patient care. Mayo Clin. Proc. 76, 299-309 (2001)
25. J.J. McCarthy, R. Hilfiker, The use of single-nucleotide polymorphism in pharmacogenomics. Nat. Biotechnol. 18, 505-508 (2000)
26. A.E. Carpenter, D.M. Sabatini, Systematic genome-wide screens of gene function. Nat. Rev. Genet. 5, 11-22 (2004)
27. S.D. Caruthers, S.A. Wickline, G.M. Lanza, Nanotechnological applications in medicine. Curr. Opin. Biotechnol. 18, 26-30 (2007)
28. M.E. Davis, Z.G. Chen, D.M. Shin, Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771-782 (2008)
29. K.K. Jain, Innovative diagnostic technologies and their significance for personalized medicine. Mol. Diagn. Ther. 14, 141-147 (2010)
30. M. Ingelman-Sundberg, Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25, 193-200 (2004)
31. K.A. Phillips, D.L. Veenstra, E. Oren, J.K. Lee, W. Sadee, Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. J. Am. Med. Assoc. 286, 2270-2279 (2001)
32. C. Gabelli, Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions. Curr. Med. Res. Opin. 19, 69-82 (2003)
33. D. Bentue-Ferrer, O. Tribut, E. Polard, H. Allain, Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 17, 947-963 (2003)
34. N.L. Henry, V. Stearns, D.A. Flockhart, D.F. Hayes, M. Riba, Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am. J. Psychiatry 165, 1251-1255 (2008)
35. J.M. Hoskins, L.A. Carey, H.L. McLeod, CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9, 576-586 (2009)
36. C.M. Kelly, D.N. Juurlink, T. Gomes, M. Duong-Hua, K.I. Pritchard, P.C. Austin, L.F. Paszat, Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Br. Med. J. 340, c693 (2010)
37. K. Sideras, J.N. Ingle, M.M. Ames, C.L. Loprinzi, D.P. Mrazek, J.L. Black, R.M. Weinshilboum, J.R. Hawse, T.C. Spelsberg, M.P. Goetz, Corescription of tamoxifen and medications that inhibit CYP2D6. J. Clin. Oncol. 28, 2768-2776 (2010)
38. T.L. Lash, C.L. Rosenberg, Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. J. Clin. Oncol. 28, 1273-1275 (2010)
39. G.E. Marchant, Small is beautiful: what can nanotechnology do for personalized medicine? Curr. Pharmacogenomics Personalized Med. 7, 231-237 (2009)
40. S. Ekins, Predicting undesirable drug interactions with promiscuous proteins in silico. Drug Discov. Today 9, 276-285 (2004)
41. S.P. Gardner, Ontologies and semantic data integration. Drug Discov. Today 10, 1001-1007 (2005)
42. I.S. Vizirianakis, The transformation of pharmacogenetics into pharmacogenomics reinforces personalized medicine towards pharmacotyping for improved patient care, in New Research on Pharmacogenetics, ed. by L.P. Barnes (Nova Science Publishers, Inc, New York, 2007), pp. 1-38
43. G. Schmitz, C. Aslanidis, K.J. Lackner, Pharmacogenomics: implications for laboratory medicine. Clin. Chim. Acta 308, 43-53 (2001)
44. D.B. Goldstein, Pharmacogenetics in the laboratory and the clinic. N. Engl. J. Med. 348, 553-556 (2003)
45. A.M. Issa, Ethical perspectives on pharmacogenomic profiling in the drug development process. Nat. Rev. Drug Discov. 1, 300-308 (2002)
46. W.W. Weber, M.D. Caldwell, J.H. Kurth, Edging toward personalized medicine. Curr. Pharmacogenomics 1, 193-202 (2003)
47. C. Debouck, P.N. Goodfellow, DNA microarrays in drug discovery and development. Nat. Genet. 21(Suppl.), 48-50 (1999)
48. I.S. Vizirianakis, Pharmaceutical education in the wake of genomic technologies for drug development and personalized medicine. Eur. J. Pharm. Sci. 15, 243-250 (2002)
49. British Pharmacological Society and the Physiological Society. Tackling the need to teach integrative pharmacology and physiology: problems and ways forward. Trends Pharmacol. Sci. 27, 130-133 (2006)
50. P.K. Manasco, P. Rieser, G. Renegar, M. Mosteller, Pharmacogenetics and the genetic basis of ADRs, in Pharmacovigilance, ed. by R.D. Mann, E.B. Andrews (West Sussex, Wiley, 2002), pp. 516-553
51. P. Farahani, M. Levine, Pharmacovigilance in a genomic era. Pharmacogenomics J. 6, 158-161 (2006)
52. B.M. Psaty, S.P. Burke, Protecting the health of the public-Institute of Medicine recommendations on drug safety. N. Engl. J. Med. 355, 1753-1755 (2006)
53. P.T. Fitzgerald, M.J. Ackerman, Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm 2, S30-S37 (2005)
54. L. Belardinelli, C. Antzelevitch, M.A. Vos, Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol. Sci. 24, 619-625 (2003)
55. C.C. Liew, V.J. Dzau, Molecular genetics and genomics of heart failure. Nat. Rev. Genet. 5, 811-825 (2004)
56. W.S. Redfern, L. Carlsson, A.S. Davis, et al., Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45 (2003)
57. R. Roberts, R. Brugada, Genetics and arrhythmias. Annu. Rev. Med. 54, 257-267 (2003)
58. A.M. Aronov, Predictive in silico modeling for hERG channel blockers. Drug Discov. Today 10, 149-155 (2005)
59. C. Napolitano, S.G. Priori, P.J. Schwartz, et al., Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. J. Am. Med. Assoc. 294, 2975-2980 (2005)
60. B. Darpo, T. Nebout, P.T. Sager, Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline. J. Clin. Pharmacol. 46, 498-507 (2006)
61. R.R. Shah, Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf. 28, 1009-1028 (2005)
62. J.C. Hancox, M.J. McPate, A. El Harchi, Y.H. Zhang, The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol. Ther. 119, 118-132 (2008)
63. N. Lee, S. Authier, M.K. Pugsley, M.J. Curtis, The continuing evolution of torsades de pointes liability testing methods: is there an end in sight? Toxicol. Appl. Pharmacol. 243, 146-153 (2010)
64. H.J. Witchel, Drug-induced hERG block and long QT syndrome. Cardiovasc. Ther. 29, 251-259 (2011)
65. I. Staudacher, P.A. Schweizer, H.A. Katus, D. Thomas, hERG: protein trafficking and potential for therapy and drug side effects. Curr. Opin. Drug. Discov. Devel. 13, 23-30 (2010)
66. E. Halapi, H. Hakonarson, Advances in the development of genetic markers for the diagnosis of disease and drug response. Expert Rev. Mol. Diagn. 2, 411-421 (2002)
67. J.A. Johnson, W.E. Evans, Molecular diagnostics as a predictive tool: genetics of drug efficacy and toxicity. Trends Mol. Med. 8, 300-305 (2002)
68. E. Dequeker, S. Ramsden, W.W. Grody, T.T. Stenzel, D.E. Barton, Quality control in molecular genetic testing. Nat. Rev. Genet. 2, 717-723 (2001)
69. D.A. Lewin, M.P. Weiner, Molecular biomarkers in drug development. Drug Discov. Today 9, 976-983 (2004)
70. A.G. Hall, S.A. Coulthard, J.A. Irving, Molecular diagnostics: a healthcare perspective. Expert Rev. Mol. Diagn. 3, 13-16 (2003)
71. B.B. Spear, M. Heath-Chiozzi, J. Huff, Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201-204 (2001)
72. K. Sangkuhl, D.S. Berlin, R.B. Altman, T.E. Klein, Pharm GKB: understanding the effects of individual genetic variants. Drug Metab. Rev. 40, 539-551 (2008)
73. D. Gurwitz, A. Weizman, M. Rehavi, Education: teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. Trends Pharmacol. Sci. 24, 122-125 (2003)
74. M.E. Van den Akker-van Marle, D. Gurwitz, S.B. Detmar, C.M. Enzing, M.M. Hopkins, E. Gutierrez deMesa, D. Ibarreta, Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics 7, 783-792 (2006)
75. D. Gurwitz, C. Rodríguez-Antona, K. Payne, W. Newman, J.P. Gisbert, E.G. de Mesa, D. Ibarreta, Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur. J. Hum. Genet. 17, 991-998 (2009)
76. N. Fleeman, C. McLeod, A. Bagust, S. Beale, A. Boland, Y. Dundar, A. Jorgensen, et al., The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol. Assess. 14, 1-157 (2010)
77. R.A. McKinnon, M.B. Ward, M.J.A. Sorich, Critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther. Clin. Risk Manag. 3, 751-759 (2007)
78. A.H.B. Wu, N. Babic, K.T.J. Yeo, Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian. Personalized Med. 6, 315-327 (2009)
79. C.R. Flowers, D. Veenstra, The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 22, 481-493 (2004)
80. K. Payne, F.H. Shabaruddin, Cost-effectiveness analysis in pharmacogenomics. Pharmacogenomics 11, 643-646 (2010)
81. W.B. Wong, J.J. Carlson, R. Thariani, D.L. Veenstra, Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics 28, 1001-1013 (2010)
82. P. Martin, W.E. Haefeli, M.A. Martin-Facklam, Drug database model as a central element for computer-supported dose adjustment within a CPOE system. J. Am. Med. Inform. Assoc. 11, 427-432 (2004)
83. S. Orphanoudakis, HYGEIAnet: the integrated regional health information network of Crete. Stud. Health Technol. Inform. 100, 66-78 (2004)
84. M. Mäakinen, J. Forsström, M. Äärimaa, et al., A European survey on the possibilities and obstacles of electronic prescriptions in cross-border healthcare. Telemed. J. E-Health 12, 484-489 (2006)
85. M.A. Keller, E.S. Gordon, C.B. Stack, N. Gharani, C.J. Sill, T.J. Schmidlen, et al., Coriell Personalized Medicine Collaborative: a prospective study of the utility of personalized medicine. Personalized Med. 7, 310-317 (2010)